Designer baby row over US clinic
By BBC,
BBC News
| 03. 02. 2009
The LA Fertility Institutes run by Dr Jeff Steinberg, a pioneer of IVF in the 1970s, expects a trait-selected baby to be born next year.
His clinic also offers sex selection.
UK fertility experts are angered that the service will distract attention from how the same technology can protect against inherited disease.
The science is based on a lab technique called preimplantation genetic diagnosis, or PGD.
This involves testing a cell taken from a very early embryo before it is put into the mother's womb.
Doctors then select an embryo free from rogue genes - or in this case an embryo with the desired physical traits such as blonde hair and blue eyes - to continue the pregnancy, and discard any others.
Dr Steinberg said couples might seek to use the clinic's services for both medical and cosmetic reasons.
For example, a couple might want to have a baby with a darker complexion to help guard against a skin cancer if they already had a child who had developed a melanoma. But others might just want a boy with blonde...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...